While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Elevating and De-Risking Your Drug Portfolio Strategy With AI
November 18th 2024Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.
Patient Engagement Throughout the Entire Product Lifecycle (October 2024)
October 17th 2024In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Using Technology and Talent to Unlock Value and Cost Savings in Patient Services
October 2nd 2024Traci Miller (Director, Sonexus™ Access and Patient Support, Cardinal Health) discusses current digital trends in the patient services industry, as well as how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.